Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

nced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net income and diluted EPS should not be viewed in isolation or as a substitute for reported, or GAAP, net income and diluted EPS.

(1) Stock option expense -- Non-GAAP net income and diluted EPS exclude

the impact of our stock option expense recorded in accordance with

SFAS No. 123R. We believe that excluding the impact of expensing stock

options better reflects the recurring economic characteristics of our

business.

(2) Other items -- Non-GAAP net income and diluted EPS exclude other

unusual or non-recurring items that are evaluated on an individual

basis. Our evaluation of whether to exclude an item for purposes of

determining our non-GAAP financial measures considers both the

quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to our ongoing business operations, and (iii) whether or not we expect

it to occur as part of our normal business on a regular basis. Items

excluded for purposes of determining non-GAAP net income and diluted

EPS include deemed dividends, preferred stock accretion, and changes

in the fair value of warrant liability.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM)
'/>"/>

SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UNION CITY, Calif., Oct. 21, 2014 Abaxis, ... company manufacturing point-of-care blood analysis systems, today reported financial ... 2014. Second quarter overview: , Revenues ... quarter. , Diluted EPS of $0.24, up 33% ... , Service revenues from Abaxis Veterinary Reference Laboratories ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... polio immunization campaign in Somalia, that will aim at vaccinating ... // ,The Head Honcho of WHO's Global Polio ... that the number of cases of polio are now beginning ... of the country which is a very difficult part of ...
... research team from Georgia Institute of Technology has developed ... (ATP) release and its role in cystic fibrosis. // ... and nano-electrodes to the tip of an atomic force ... monitor topography along with electrochemical activity at the cell ...
... down. The industry across the country is now facing a suicide ... the country, small farmers are scared due to low prices. // ... Rs 5 for one kg of chicken from Rs 1.80 and ... being forced to commit suicide. K Narayana Reddy, president, of Andhra ...
... study in Australia has found that babies born to women, ... birth weight and lower APGAR scores and are more likely ... women have a higher number of previous pregnancies, smoke more ... to the study in the April issue of Alcoholism: Clinical ...
... clot formation in both men and women according to a new ... cell testing in both sexes with 81 milligrams of acetyl salicylic ... platelets – the clot-forming cells. Clots in blood vessels of the ... while the drug's overall effects on blood cell function were the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Use Of Alcohol During Pregnancy Affects Newborns 2Health News:Low-dose Aspirin Benefits Both Sexes 2Health News:Low-dose Aspirin Benefits Both Sexes 3Health News:Low-dose Aspirin Benefits Both Sexes 4
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Handheld Digital Retinal Camera...
Inquire...
Specifically for placing follicular units....
Medicine Products: